PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.32%
Negative revenue growth while ECL.AX stands at 1.03%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-14.32%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-67.18%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-67.18%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-175.62%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-200.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-200.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
14.57%
Slight or no buybacks while ECL.AX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
13.52%
Slight or no buyback while ECL.AX is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
135.18%
OCF growth under 50% of ECL.AX's 3933.20%. Michael Burry might suspect questionable revenue recognition or rising costs.
107.63%
FCF growth under 50% of ECL.AX's 3968.80%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-77.23%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-9.90%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
36.51%
3Y revenue/share CAGR under 50% of ECL.AX's 82.74%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-89.51%
Negative 10Y OCF/share CAGR while ECL.AX stands at 179.34%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-58.37%
Negative 5Y OCF/share CAGR while ECL.AX is at 111.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-87.67%
Negative 3Y OCF/share CAGR while ECL.AX stands at 146.51%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
49.18%
Below 50% of ECL.AX's 416.07%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-32.00%
Negative 5Y net income/share CAGR while ECL.AX is 113.08%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1200.00%
Negative 3Y CAGR while ECL.AX is 40.31%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
25549.17%
5Y equity/share CAGR above 1.5x ECL.AX's 0.87%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
265.66%
3Y equity/share CAGR above 1.5x ECL.AX's 14.49%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-77.83%
Firm’s AR is declining while ECL.AX shows 9.55%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
49.04%
We show growth while ECL.AX is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.45%
Asset growth above 1.5x ECL.AX's 0.24%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-22.22%
We have a declining book value while ECL.AX shows 10.69%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.16%
Debt growth of 0.16% while ECL.AX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
55.65%
R&D growth of 55.65% while ECL.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
15.36%
SG&A growth well above ECL.AX's 2.96%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.